🔎 Trials Near Me

Home › Parkinson's Disease › NCT06285643

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

RecruitingPhase 2

A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults With Moderate Stage Parkinson's Disease

Who can join

Ages 45 to 75 · All sexes

Full eligibility criteria
Inclusion Criteria:

Age

1. Male and female adults 45-75 years of age inclusive, at the time of signing of informed consent Type of Subject and Disease Characteristics
2. Diagnosed with Parkinson's disease in the past 4-10 years (inclusive) as defined by the following:

   1. Presence of bradykinesia PLUS any of the following:

      * Rigidity
      * Rest tremor
      * Postural instability
   2. Presence of motor fluctuations as measured by the PD Motor Diary
   3. Stable anti-parkinsonian medication regimen for \>/= 4 weeks prior to screening
   4. Must demonstrate responsiveness to levodopa therapy

Exclusion Criteria:

* Known history or current evidence of medical, genetic, or neurological conditions that may provide an alternative to idiopathic PD diagnosis
* Presence or history of significant vascular and/or cardiovascular disease
* Presence of significant cognitive impairment, poorly controlled depression/anxiety
* Presence or history of psychosis or impulse control disorder
* History of malignancy other than treated cutaneous squamous or basal cell carcinomas
* Presence of clinically relevant conditions that could compromise surgical suitability and/or subject safety
* Contraindication to magnetic resonance imaging and/or use gadolinium-based contrast agents
* Prior history of brain surgery including, but no limited: DBS, pallidotomy focused ultrasound thalamotomy, or other experimental neurosurgical procedure
* Chronic immunosuppressive therapy

About the study

The objective of this randomized, surgically controlled, double-blinded, Phase 2 study is to evaluate the safety and efficacy of AAV2-GDNF delivered to the putamen in subjects with moderate Parkinson's Disease.

What is being tested

Sponsor: AskBio Inc · Participants: 127 · Started: Jun 11, 2024

Contact the study team

Official record on ClinicalTrials.gov — NCT06285643

Locations in the U.S.

ArizonaMayo Clinic, Phoenix (Not yet recruiting)
CaliforniaUCI Alpha Clinic (Neurology), Irvine
Loma Linda University (Neurology), Loma Linda
University of California San Francisco (Neurology), San Francisco
ColoradoCenExel Rocky Mountain Clinical Research (Neurology), Englewood
District of ColumbiaGeorgetown University (Neurology), Washington D.C.
FloridaParkinson's Disease and Movement Disorders Center of Boca Raton (Neurology), Boca Raton
University of Florida, Gainesville (Not yet recruiting)
University of Miami, Miami (Not yet recruiting)
Orlando Health Neuroscience Institute, Orlando
Parkinson's Disease Treatment Center of Southwest Florida (Neurology), Port Charlotte
IllinoisRush University Medical Center (Neurology), Chicago
KansasUniversity of Kansas Medical Center (Neurology), Kansas City
MassachusettsMassachusetts General Hospital (Neurology), Boston
MichiganMichigan State University (Neurology), East Lansing
Quest Research Institute (Neurology), Farmington Hills
NevadaCleveland Clinic Lou Ruvo (Neurology), Las Vegas
New YorkColumbia University, New York
North CarolinaUniversity of North Carolina (Neurology), Chapel Hill
Duke University (Neurology), Durham
PennsylvaniaUniversity of Pennsylvania (Neurology), Philadelphia
TennesseeVanderbilt University (Neurology), Nashville
TexasTexas Movement Disorder Specialists, Georgetown (Not yet recruiting)
Houston Methodist (Neurology), Houston
UtahUniversity of Utah, Salt Lake City (Not yet recruiting)
WashingtonEvergreenHealth Research Department (Neurology), Kirkland
WisconsinUniversity of Wisconsin (Neurology), Madison

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.